# Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

> **NCT00097812** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 220 (—)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00097812
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 220 (—)
- **Last updated:** 2012-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097812, "Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00097812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*